ATE115410T1 - Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind. - Google Patents

Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind.

Info

Publication number
ATE115410T1
ATE115410T1 AT90908772T AT90908772T ATE115410T1 AT E115410 T1 ATE115410 T1 AT E115410T1 AT 90908772 T AT90908772 T AT 90908772T AT 90908772 T AT90908772 T AT 90908772T AT E115410 T1 ATE115410 T1 AT E115410T1
Authority
AT
Austria
Prior art keywords
fibrin
plasminogen
plasminogen activator
fragments
thrombus
Prior art date
Application number
AT90908772T
Other languages
English (en)
Inventor
Andrei Z Budzynski
Linda C Knight
Ahmed Ak Hasan
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Application granted granted Critical
Publication of ATE115410T1 publication Critical patent/ATE115410T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
AT90908772T 1989-05-24 1990-05-21 Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind. ATE115410T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35697889A 1989-05-24 1989-05-24

Publications (1)

Publication Number Publication Date
ATE115410T1 true ATE115410T1 (de) 1994-12-15

Family

ID=23403780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90908772T ATE115410T1 (de) 1989-05-24 1990-05-21 Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind.

Country Status (7)

Country Link
US (1) US5288490A (de)
EP (1) EP0473689B1 (de)
JP (1) JPH04505326A (de)
AT (1) ATE115410T1 (de)
CA (1) CA1335361C (de)
DE (1) DE69015182T2 (de)
WO (1) WO1990014102A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001355A (en) * 1982-12-14 1999-12-14 Dowdle; Eugene Bernard Davey Pro-tPA for the treatment of thrombosis, embolism and related conditions
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
CN1091315A (zh) * 1992-10-08 1994-08-31 E·R·斯奎布父子公司 血纤维蛋白封闭剂组合物及其使用方法
DE4242736A1 (de) * 1992-12-17 1994-06-23 Behringwerke Ag Synthetische Peptide, Antikörper dagegen und ihre Verwendung
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
DE4442665A1 (de) * 1994-11-30 1996-06-05 Gruenenthal Gmbh Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften
US6599515B1 (en) * 1995-01-16 2003-07-29 Baxter International Inc. Fibrin porous structure
US5951981A (en) * 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
AU3221599A (en) * 1998-04-03 1999-10-25 Daily Wellness Company, The Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
DE60033932T2 (de) * 1999-06-05 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Methode und zusammensetzung zur inhibierung von kardiovaskulärer zellproliferation
EP1130031A1 (de) * 2000-02-25 2001-09-05 Universitair Medisch Centrum Utrecht Verfahren zur Hemmung der Angiogenese unter Verwendung von Molekülen die die Plasminbildung steigern oder die Plasminaktivität verlängern
US6989164B2 (en) * 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6497885B2 (en) * 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
EP1380290A1 (de) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
CA2557814A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
JP4471867B2 (ja) * 2005-02-25 2010-06-02 シスメックス株式会社 Ｄダイマー測定用標準物質
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
EP1907864A2 (de) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. Verfahren zur bestimmung der auswirkung einer behandlung auf den cross-beta struktur-gehalt eines proteins; auswahl von behandlungen und verwendungen davon
US20080118529A1 (en) * 2005-07-13 2008-05-22 Gebbink Martijn Frans Ben Gera Adjuvation Through Cross -Beta Structure
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
US8067187B2 (en) * 2005-07-13 2011-11-29 Crossbeta Biosciences B.V. Cross-β structure binding compounds
EP2058000A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
EP2058001A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Steigerung der Immunogenizität von Antigenen
FR2979635B1 (fr) * 2011-09-07 2015-03-20 Hyphen Biomed Procede de dosage du plasminogene en milieu liquide, compositions et kit associes.
DE102014112212A1 (de) 2014-08-26 2016-03-03 Akesion Gmbh Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen
JP7028904B2 (ja) * 2019-03-21 2022-03-02 アカデミア シニカ 合成ペプチド、それを備える薬学的組成物及び血栓塞栓症関連疾患の治療におけるその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) * 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4536391A (en) * 1982-11-17 1985-08-20 Otsuka Pharmaceutical Co. Process for preparing urokinase complex
SU1128601A1 (ru) * 1983-05-10 1985-07-15 Всесоюзный кардиологический научный центр АМН СССР Урокиназа,иммобилизированна на фибриногене
GB8400653D0 (en) * 1984-01-11 1984-02-15 Beecham Group Plc Conjugates

Also Published As

Publication number Publication date
WO1990014102A1 (en) 1990-11-29
US5288490A (en) 1994-02-22
EP0473689A4 (en) 1992-07-15
JPH04505326A (ja) 1992-09-17
DE69015182D1 (de) 1995-01-26
DE69015182T2 (de) 1995-05-24
EP0473689A1 (de) 1992-03-11
EP0473689B1 (de) 1994-12-14
CA1335361C (en) 1995-04-25

Similar Documents

Publication Publication Date Title
ATE115410T1 (de) Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind.
Stamler et al. S-nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme.
Plow et al. Plasminogen receptors in the mediation of pericellular proteolysis
SE8800238D0 (sv) Flytande enzymkompositioner
DE3766157D1 (de) Kupplungsmittel zum radiomarkieren von proteinen.
DK0973806T3 (da) Sted-beskyttet proteinmodificering
GB1533205A (en) Plasmin fractions and complexes thereof
EP0355068A3 (de) Rekombinante Hybrid-Immunoglobulin-Moleküle sowie deren Verwendung
Urano et al. Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity
DE3061429D1 (en) Improved method for preparing plasminogen activator, activator thus obtained and medicine comprising it
EP0290118A3 (de) Fibrinolytisch wirksames Enzym
Robbins et al. A covalent molecular weight. apprx. 92,000 hybrid plasminogen activator derived from human plasmin fibrin-binding and tissue plasminogen activator catalytic domains
Liang et al. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs
Rijken et al. Interaction of plasminogen activators and plasminogen with heparin: effect of ionic strength
Okada et al. Effects of fibrin and α2‐antiplasmin on plasminogen activation by staphylokinase
ES8603951A1 (es) Un metodo de estabilizar el zimogeno de uroquinasa
Loscalzo An overview of thrombolytic agents
Sakharov et al. Two-step targeting of urokinase to plasma clot provides efficient fibrinolysis
DE69434220D1 (de) Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen
Robinson et al. Slow clearance of acylated, hybrid thrombolytic enzymes
KR900004351A (ko) 하이브리드 단일클론 항체, 그의 제조방법 및 용도
Takahashi et al. Affinity chromatography for purification of two urokinases from human urine
Devlin et al. 283 A comparison of hybrid plasminogen activators containing two different kringle domains
Leonardsson et al. 284 Characterization of the cDNA for rat tPA
Kawamura et al. The effects of polysaccharides on plasminogen activation by single chain-and two chain-tissue plasminogen activator

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties